By Samuel Indyk
Investing.com – Omega Diagnostics Group Plc (LON:ODX) has issued a statement after the UK Rapid Test Consortium (UK-RTC) issued a press release presenting new data relating to the performance of their AbC-19 rapid antibody test when used as a companion diagnostic to the Pfizer Inc (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) vaccine.
During the University of Birmingham study, the company’s AbC-19 rapid test was used to test individuals who had been given a single dose of the Pfizer-BioNTech vaccine. The company notes that from the data, the AbC-19 rapid antibody test was effective in demonstrating immune response following first dose vaccination.
UK-RTC statement
"The initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination,” the UK-RTC said in a statement.
“Should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings."